← Back to Search

Radiation Therapy

Hypofractionated Radiation Therapy for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Michael Farris, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 and 2 years after first post-radiotherapy scan
Awards & highlights

Summary

This trial is testing a new way of doing radiation therapy for lung cancer that may have better effects than the standard approach.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 and 2 years after first post-radiotherapy scan
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 and 2 years after first post-radiotherapy scan for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Presence or Absence of In-Field Progression
Secondary study objectives
Overall Survival
Progression-Free Survival
Proportion of Participants Experiencing Grade 2 or Higher Toxicities
+1 more

Side effects data

From 2023 Phase 3 trial • 107 Patients • NCT03324802
80%
Dermatitis radiation
54%
Skin hyperpigmentation
48%
Pain
35%
Lymphedema
22%
Superficial soft tissue fibrosis
7%
Skin hypopigmentation
6%
Edema limbs
2%
Device related infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm 1 (Radiation Therapy, 15 Fractions)
Arm 2 (Hypofractionated Radiation Therapy, 5 Fractions)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hypofractionated Radiation TherapyExperimental Treatment2 Interventions
Hypofractionated radiation therapy will be delivered to all participants. The radiation will be planned in a special way to give the biggest parts of the tumors that are the most difficult to control a little more radiation every day than the lower risk areas.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hypofractionated Radiation Therapy
2016
Completed Phase 3
~130

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,999 Total Patients Enrolled
Wake Forest University Health SciencesLead Sponsor
1,266 Previous Clinical Trials
1,013,706 Total Patients Enrolled
Michael Farris, MDPrincipal InvestigatorWake Forest University Health Sciences
6 Previous Clinical Trials
201 Total Patients Enrolled
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top